定期移动应用(eMOM)结合血糖与生活方式自我追踪在无人工指导情况下改善饮食控制的妊娠期糖尿病治疗:一项随机对照试验
该随机对照试验将148名饮食控制的妊娠期糖尿病患者在孕24至28周按1:1分为干预组(标准护理+eMOM)和对照组(仅标准护理)。干预组使用eMOM配合连续血糖监测、活动追踪器和饮食日记每月1周至分娩。结果显示干预组空腹血糖变化更优、毛细血管空腹血糖更低、蔬菜摄入增加、久坐减少、轻体力活动增加、妊娠期增重更少且巨大儿更少,依从性高且使用与多项指标改善相关,但妊娠并发症无显著组间差异。
要点
- eMOM干预组空腹血糖变化低于对照组(差异-0.15 mmol/L vs -2.7 mg/mL;P=.022)。
- 干预组妊娠期增重更少(差异-1.3 kg;P=.015),巨大儿更少(差异-13.1%;P=.036)。
- eMOM每日使用>90%,使用与更低空腹和餐后血糖、更少增重及更多活动相关。
核心结论
- 自我追踪生活方式因素和血糖水平无需额外指导即可改善自我管理和妊娠期糖尿病治疗,并使新生儿获益。
- 研究结果支持在产科护理中使用数字自我管理和教育工具。
研究设计与样本
- 随机对照试验,在孕24至28周按1:1比例随机分配至干预组或对照组。
- 共148名饮食控制的妊娠期糖尿病患者(干预组76名,对照组72名;平均年龄34.1±4.0岁;体重指数27.1±5.0 kg/m2)。
- 干预组接受标准护理联合eMOM(连续血糖监测、活动追踪器和饮食日记,每月1周至分娩),对照组仅接受标准护理。
主要发现
- 干预组空腹血浆葡萄糖平均变化低于对照组(差异-0.15 mmol/L vs -2.7 mg/mL;P=.022)。
- 干预组毛细血管空腹血糖水平低于对照组(差异-0.04 mmol/L vs -0.7 mg/mL;P=.002)。
- 与对照组相比,干预组蔬菜摄入增加(差异11.8 g/MJ;P=.043)、久坐行为减少(差异-27.3 min/d;P=.043)、轻体力活动增加(差异22.8 min/d;P=.009)。
- 干预组妊娠期增重更少(差异-1.3 kg;P=.015),巨大儿更少(差异-13.1%;P=.036)。
- eMOM依从性高(每日使用>90%),使用与更低母体空腹血糖(P=.0006)和餐后血糖(P=.017)、增重(P=.028)、能量摄入(P=.021)和碳水化合物摄入(P=.003)及每日体力活动时间更长(P=.0006)相关;妊娠并发症无显著组间差异。
临床怎么用
- 作者认为自我追踪生活方式因素和血糖水平无需额外指导即可改善自我管理和妊娠期糖尿病治疗,并使新生儿获益。
- 作者认为研究结果支持在产科护理中使用数字自我管理和教育工具。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Digitalization with minimal human resources could support self-management among women with gestational diabetes and improve maternal and neonatal outcomes. OBJECTIVE: This study aimed to investigate if a periodic mobile application (eMOM) with wearable sensors improves maternal and neonatal outcomes among women with diet-controlled gestational diabetes without additional guidance from healthcare personnel. STUDY DESIGN: Women with gestational diabetes were randomly assigned in a 1:1 ratio at 24 to 28 weeks' gestation to the intervention or the control arm. The intervention arm received standard care in combination with use of the periodic eMOM, whereas the control arm received only standard care. The intervention arm used eMOM with a continuous glucose monitor, an activity tracker, and a food diary 1 week/month until delivery. The primary outcome was the change in fasting plasma glucose from baseline to 35 to 37 weeks' gestation. Secondary outcomes included capillary glucose, weight gain, nutrition, physical activity, pregnancy complications, and neonatal outcomes, such as macrosomia. RESULTS: In total, 148 women (76 in the intervention arm, 72 in the control arm; average age, 34.1±4.0 years; body mass index, 27.1±5.0 kg/m2) were randomized. The intervention arm showed a lower mean change in fasting plasma glucose than the control arm (difference, -0.15 mmol/L vs -2.7 mg/mL; P=.022) and lower capillary fasting glucose levels (difference, -0.04 mmol/L vs -0.7 mg/mL; P=.002). The intervention arm also increased their intake of vegetables (difference, 11.8 g/MJ; P=.043), decreased their sedentary behavior (difference, -27.3 min/d; P=.043), and increased light physical activity (difference, 22.8 min/d; P=.009) when compared with the control arm. In addition, gestational weight gain was lower (difference, -1.3 kg; P=.015), and there were less newborns with macrosomia in the intervention arm (difference, -13.1 %; P=.036). Adherence to eMOM was high (daily use >90%), and the usage correlated with lower maternal fasting (P=.0006) and postprandial glucose levels (P=.017), weight gain (P=.028), intake of energy (P=.021) and carbohydrates (P=.003), and longer duration of the daily physical activity (P=.0006). There were no significant between-arm differences in terms of pregnancy complications. CONCLUSION: Self-tracking of lifestyle factors and glucose levels without additional guidance improves self-management and the treatment of gestational diabetes, which also benefits newborns. The results of this study support the use of digital self-management and education tools in maternity care.
引用
- Kytö M, Hotta S, Niinistö S, et al. Periodic mobile application (eMOM) with self-tracking of glucose and lifestyle improves treatment of diet-controlled gestational diabetes without human guidance: a randomized controlled trial. Am J Obstet Gynecol. 2024. PMID: 38432415. doi:10.1016/j.ajog.2024.02.303
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。